ema semaglutide expands probe of possible suicide risk to popular weight loss, diabetes drugs EU investigates Ozempic, weight-loss drug

Medical service experts must be cautious when prescribing this medicine to persons on multiple medicines

What is already known on this topic Glucagon-like peptide-1 (GLP-1) is involved in the development of impaired gallbladder motility Liraglutide, an important member of the GLP-1 receptor agonist class, has been reported to be associated with an increased risk of gallbladder or biliary diseases Glucose dependent insulinotropic polypeptide has also been reported to affect gallbladder motility What this study adds Dipeptidyl peptidase-4 (DPP-4) inhibitors were significantly associated with an increased risk of the composite of gallbladder or biliary diseases and cholecystitis DPP-4 inhibitors were not associated with increased risk of cholelithiasis and biliary diseases Risk of cholecystitis was increased with DPP-4 inhibitors compared with sodium-glucose cotransporter-2 inhibitors but not GLP-1 receptor agonists Ethics statements Ethical approval Not needed

For example, an apple is a whole food

I experienced minor redness at injection sites during the first two weeks that went away on its own

Biotech Primer is your go-to source for interactive training across the biotechnology, pharmaceutical, molecular diagnostics, and medical device sectors

Supplementing can help support the repair process, making it easier to stay consistent with your training